30:16Next to Lead

Next to Lead
Big Pharma's trust gap? How Gilead is rewriting the narrative | Next to Lead
Latest episode
Gilead Sciences moves at a pace rarely seen in pharma, delivering breakthrough COVID-19 antivirals and HIV preventatives in record time. Yet, in an industry facing a massive trust deficit, speed isn’t always enough. In this episode of Next to Lead, Johanna Mercier, Gilead’s Chief Commercial & Corporate Affairs Officer, joins Fortune’s Leadership Editor Ruth Umoh to discuss how the company is rewriting its narrative and balancing its patients with its shareholders.
Episodes (18 episodes)
30:16
22:23
38:31
36:55
2:04
38:46
37:26
36:38
37:45
36:09
37:49
36:39
37:37
39:10
33:28
41:37
36:18
37:30